Iwona Gorczyca-Głowacka, Łukasz Nawacki, Magdalena Kołomańska, Robert Mazurkiewicz, Marcin Niżnik, Krzysztof Ratnicki, Małgorzata Czerniak, Piotr Myrcha, Maciej Bękarski, Joao Rocha-Neves, Juliana Pereira-Macedo, Kryspin Mitura, Laura Kacprzak, Małgorzata Pajer, Piotr Richter, Kamil Rapacz, Maciej Sroczyński, Mateusz Szmit, Stanisław Głuszek
{"title":"瘦人患者代谢功能障碍相关脂肪变性肝病的临床特征和危险因素：波兰胆结石手术登记处的结果","authors":"Iwona Gorczyca-Głowacka, Łukasz Nawacki, Magdalena Kołomańska, Robert Mazurkiewicz, Marcin Niżnik, Krzysztof Ratnicki, Małgorzata Czerniak, Piotr Myrcha, Maciej Bękarski, Joao Rocha-Neves, Juliana Pereira-Macedo, Kryspin Mitura, Laura Kacprzak, Małgorzata Pajer, Piotr Richter, Kamil Rapacz, Maciej Sroczyński, Mateusz Szmit, Stanisław Głuszek","doi":"10.5114/ceh.2025.151805","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim of the study: </strong>Data concerning the clinical manifestation and outcomes of lean metabolic dysfunction-associated steatotic liver disease (MASLD) are scarce and inconsistent. The aim of the study was to evaluate the clinical characteristics of MASLD and predictors of its occurrence.</p><p><strong>Material and methods: </strong>The study included patients from the Polish Gallstone Surgery Registry diagnosed with MASLD according to the current criteria.</p><p><strong>Results: </strong>Among 3,419 patients, MASLD was diagnosed in 24.2%. Lean MASLD was diagnosed in 11.3% of patients with MASLD. Independent predictors of lean MASLD were atherogenic dyslipidaemia (OR = 94.16, CI: 45.54-197.71, <i>p</i> < 0.0001), diabetes mellitus or prediabetes conditions (OR = 9.26, CI: 4.42-19.38, <i>p</i> < 0.0001) and hypertension (OR = 2.97, CI: 1.38-6.41, <i>p</i> = 0.0054).</p><p><strong>Conclusions: </strong>Lean MASLD is not a rare form of the disease, and in the lean MASLD group there are patients with a high rate of metabolic abnormalities which may significantly increase cardiovascular risk and the risk of MASLD progression.</p>","PeriodicalId":10281,"journal":{"name":"Clinical and Experimental Hepatology","volume":"11 2","pages":"160-168"},"PeriodicalIF":1.7000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12403726/pdf/","citationCount":"0","resultStr":"{\"title\":\"Clinical characteristics and risk factors of metabolic dysfunction-associated steatotic liver disease in lean patients: results of the Polish Gallstone Surgery Registry.\",\"authors\":\"Iwona Gorczyca-Głowacka, Łukasz Nawacki, Magdalena Kołomańska, Robert Mazurkiewicz, Marcin Niżnik, Krzysztof Ratnicki, Małgorzata Czerniak, Piotr Myrcha, Maciej Bękarski, Joao Rocha-Neves, Juliana Pereira-Macedo, Kryspin Mitura, Laura Kacprzak, Małgorzata Pajer, Piotr Richter, Kamil Rapacz, Maciej Sroczyński, Mateusz Szmit, Stanisław Głuszek\",\"doi\":\"10.5114/ceh.2025.151805\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aim of the study: </strong>Data concerning the clinical manifestation and outcomes of lean metabolic dysfunction-associated steatotic liver disease (MASLD) are scarce and inconsistent. The aim of the study was to evaluate the clinical characteristics of MASLD and predictors of its occurrence.</p><p><strong>Material and methods: </strong>The study included patients from the Polish Gallstone Surgery Registry diagnosed with MASLD according to the current criteria.</p><p><strong>Results: </strong>Among 3,419 patients, MASLD was diagnosed in 24.2%. Lean MASLD was diagnosed in 11.3% of patients with MASLD. Independent predictors of lean MASLD were atherogenic dyslipidaemia (OR = 94.16, CI: 45.54-197.71, <i>p</i> < 0.0001), diabetes mellitus or prediabetes conditions (OR = 9.26, CI: 4.42-19.38, <i>p</i> < 0.0001) and hypertension (OR = 2.97, CI: 1.38-6.41, <i>p</i> = 0.0054).</p><p><strong>Conclusions: </strong>Lean MASLD is not a rare form of the disease, and in the lean MASLD group there are patients with a high rate of metabolic abnormalities which may significantly increase cardiovascular risk and the risk of MASLD progression.</p>\",\"PeriodicalId\":10281,\"journal\":{\"name\":\"Clinical and Experimental Hepatology\",\"volume\":\"11 2\",\"pages\":\"160-168\"},\"PeriodicalIF\":1.7000,\"publicationDate\":\"2025-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12403726/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical and Experimental Hepatology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5114/ceh.2025.151805\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/6/9 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Hepatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5114/ceh.2025.151805","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/9 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
研究目的：关于瘦代谢功能障碍相关脂肪变性肝病（MASLD）的临床表现和预后的数据很少且不一致。本研究的目的是评估MASLD的临床特征及其发生的预测因素。材料和方法：研究纳入了波兰胆结石手术登记处根据现行标准诊断为MASLD的患者。结果：3419例患者中，MASLD确诊率为24.2%。11.3%的MASLD患者被诊断为精益型MASLD。瘦MASLD的独立预测因子为动脉粥样硬化性血脂异常血症（OR = 94.16, CI: 45.54-197.71, p < 0.0001）、糖尿病或糖尿病前期状况（OR = 9.26, CI: 4.42-19.38, p < 0.0001）和高血压（OR = 2.97, CI: 1.38-6.41, p = 0.0054）。结论：瘦型MASLD并不是一种罕见的疾病，在瘦型MASLD组中，患者的代谢异常率很高，这可能会显著增加心血管风险和MASLD进展的风险。
Clinical characteristics and risk factors of metabolic dysfunction-associated steatotic liver disease in lean patients: results of the Polish Gallstone Surgery Registry.
Aim of the study: Data concerning the clinical manifestation and outcomes of lean metabolic dysfunction-associated steatotic liver disease (MASLD) are scarce and inconsistent. The aim of the study was to evaluate the clinical characteristics of MASLD and predictors of its occurrence.
Material and methods: The study included patients from the Polish Gallstone Surgery Registry diagnosed with MASLD according to the current criteria.
Results: Among 3,419 patients, MASLD was diagnosed in 24.2%. Lean MASLD was diagnosed in 11.3% of patients with MASLD. Independent predictors of lean MASLD were atherogenic dyslipidaemia (OR = 94.16, CI: 45.54-197.71, p < 0.0001), diabetes mellitus or prediabetes conditions (OR = 9.26, CI: 4.42-19.38, p < 0.0001) and hypertension (OR = 2.97, CI: 1.38-6.41, p = 0.0054).
Conclusions: Lean MASLD is not a rare form of the disease, and in the lean MASLD group there are patients with a high rate of metabolic abnormalities which may significantly increase cardiovascular risk and the risk of MASLD progression.
期刊介绍：
Clinical and Experimental Hepatology – quarterly of the Polish Association for Study of Liver – is a scientific and educational, peer-reviewed journal publishing original and review papers describing clinical and basic investigations in the field of hepatology.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
